Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01391689 · ClinicalTrials.gov registry record · NA
Diindolylmethane in Treating Patients With Breast Cancer
A NA study of Stage II Breast Cancer and Stage IIIA Breast Cancer, sponsored by University of Arizona.
- Completed
- Registry status
- NA
- Development phase
- 144
- Enrollment target
- 1
- Study location
NCT01391689: Completed NA study of Stage II Breast Cancer and Stage IIIA Breast Cancer, sponsored by University of Arizona.
NCT01391689 is a NA study of Stage II Breast Cancer and Stage IIIA Breast Cancer that has completed, run by University of Arizona. The registered enrollment target is 144 participants, below the 314-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01391689, a NA study of Stage II Breast Cancer and Stage IIIA Breast Cancer, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- NA
- Development phase
- 144 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II/III trial studies how well diindolylmethane (DIM) works and compares it to placebo in treating patients with breast cancer. DIM may slow the growth of tumor cells and be an effective treatment for breast cancer.
Primary Outcome
estrogen metabolites measured in ng/100ul; this outcome will also be reported as a ratio
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT placebo
- DIETARY_SUPPLEMENT diindolylmethane
Study Locations (1)
Arizona
- Arizona Cancer Center - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2011-02 |
| Est. Completion | 2016-07-31 |
| Phase | NA |
What the finished NCT01391689 record still lists
NCT01391689 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 314-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (54% lower).
The record links to 4 conditions, with Stage II Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01391689 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT01391689 about?
NCT01391689 is a clinical study titled "Diindolylmethane in Treating Patients With Breast Cancer". This phase II/III trial studies how well diindolylmethane (DIM) works and compares it to placebo in treating patients with breast cancer. DIM may slow the growth of tumor cells and be an effective treatment for breast cancer.
What is the current status of trial NCT01391689?
This trial is currently completed. It is a NA study. The enrollment target is 144 participants. The study started on 2011-02. Estimated completion is 2016-07-31.
What conditions does trial NCT01391689 study?
This clinical trial studies the following conditions: Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer.
What interventions are being tested in trial NCT01391689?
The interventions under investigation include: placebo (DIETARY_SUPPLEMENT), diindolylmethane (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01391689?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01391689 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01391689's enrollment target sits among peer trials
144 11th of 30 higher than 20 of 30 other Stage II Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage II Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
RECRUITING · NA
-
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
RECRUITING · NA
-
Improving Exercise Capacity With a Tailored Physical Activity Intervention
RECRUITING · NA
-
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
ACTIVE NOT RECRUITING · NA
-
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
ACTIVE NOT RECRUITING · NA
-
Researching the Effect of Exercise on Cancer
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia